Recombinant human erythropoietin: possible role as an antioxidant in premature rabbits
- PMID: 8865272
- DOI: 10.1203/00006450-199609000-00003
Recombinant human erythropoietin: possible role as an antioxidant in premature rabbits
Abstract
Iron is an important catalyst for free oxygen radicals and lipid peroxidation reactions which may play a role in the pathogenesis of several diseases in premature infants. During the early neonatal period, extracellular iron is available in excessive amounts. We hypothesized that administration of erythropoietin (EPO) mobilizes iron from plasma and inhibits iron-catalyzed reactions. To evaluate this hypothesis, recombinant human EPO (rhEPO) was administered s.c. to premature rabbits delivered at 29-d gestation: one group was kept in room air (RA) and the other in a 100% oxygen environment. Within each group, the animals were randomized to receive placebo or rhEPO at 400 or at 800 U/kg on d 0 and 2 of life. On d 3 or 4, plasma iron and iron saturation of transferrin were assessed. Lipid peroxidation was analyzed in plasma and bronchoalveolar lavage fluid (BAL). Nonsedimentable protein (NSP) and phospholipid content were measured in BAL. Erythropoiesis was evaluated in liver and bone marrow. Treatment with rhEPO decreased plasma iron, decreased iron saturation of transferrin, increased reticulocytes, and increased erythropoiesis in liver and bone marrow in both RA and hyperoxia group. Oxygen exposure increased NSP in BAL and decreased the ability of BAL to inhibit lipid peroxidation as measured by malondialdehyde (MDA) generation compared with RA exposure. In O2-exposed animals, EPO treatment increased the ability of both plasma (EPO 800) and BAL (EPO 400 and 800) to inhibit lipid peroxidation and decreased NSP in BAL (EPO 400). In addition, rhEPO treatment decreased alveolar thickening and proteinaceous exudate in the hyperoxia group. We propose that by stimulating erythropoiesis, rhEPO mobilizes non-heme iron and decreases oxidant injury that depends on the availability of transient metal.
Similar articles
-
Early treatment of premature infants with recombinant human erythropoietin.Pediatrics. 1993 Oct;92(4):519-23. Pediatrics. 1993. PMID: 8414820 Clinical Trial.
-
Transferrin modifies surfactant responsiveness in acute respiratory failure: role of iron-free transferrin as an antioxidant.Pediatr Pulmonol. 1996 Jul;22(1):14-22. doi: 10.1002/(SICI)1099-0496(199607)22:1<14::AID-PPUL3>3.0.CO;2-K. Pediatr Pulmonol. 1996. PMID: 8856799
-
Inhaled nitric oxide decreases hyperoxia-induced surfactant abnormality in preterm rabbits.Pediatr Res. 1999 Feb;45(2):247-54. doi: 10.1203/00006450-199902000-00016. Pediatr Res. 1999. PMID: 10022598
-
Erythropoietin and transferrin metabolism in nephrotic syndrome.Am J Kidney Dis. 2001 Jul;38(1):1-8. doi: 10.1053/ajkd.2001.25174. Am J Kidney Dis. 2001. PMID: 11431174 Review.
-
Metal-induced hepatotoxicity.Semin Liver Dis. 1996 Feb;16(1):3-12. doi: 10.1055/s-2007-1007214. Semin Liver Dis. 1996. PMID: 8723319 Review.
Cited by
-
Relation Between Gender and Concomitant Medications With Erythropoietin-Treatment on Wound Healing in Burn Patients. Post Hoc Subgroup-Analysis of the Randomized, Placebo-Controlled Clinical Trial "EPO in Burns".Front Pharmacol. 2022 Jul 1;13:812888. doi: 10.3389/fphar.2022.812888. eCollection 2022. Front Pharmacol. 2022. PMID: 35847006 Free PMC article.
-
Ferroptosis: A Promising Therapeutic Target for Neonatal Hypoxic-Ischemic Brain Injury.Int J Mol Sci. 2022 Jul 4;23(13):7420. doi: 10.3390/ijms23137420. Int J Mol Sci. 2022. PMID: 35806425 Free PMC article. Review.
-
Erythropoietin in Optic Neuropathies: Current Future Strategies for Optic Nerve Protection and Repair.Int J Mol Sci. 2022 Jun 27;23(13):7143. doi: 10.3390/ijms23137143. Int J Mol Sci. 2022. PMID: 35806148 Free PMC article. Review.
-
The Potential Role of Ferroptosis in Neonatal Brain Injury.Front Neurosci. 2019 Feb 14;13:115. doi: 10.3389/fnins.2019.00115. eCollection 2019. Front Neurosci. 2019. PMID: 30837832 Free PMC article. Review.
-
Bronchopulmonary Dysplasia: An Update of Current Pharmacologic Therapies and New Approaches.Clin Med Insights Pediatr. 2018 Dec 11;12:1179556518817322. doi: 10.1177/1179556518817322. eCollection 2018. Clin Med Insights Pediatr. 2018. PMID: 30574005 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials